The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats

European Journal of Pharmacology

Volumn 507, Issue 1-3, 2005, Pages 291-299

  El Medany, Azza ^a   Mahgoub, Afaf ^a   Mustafa, Ali ^a   Arafa, Maha ^b   Morsi, Mahmoud ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c MINISTRY OF HEALTH   (Saudi Arabia)

Author keywords

Acetic acid induced colitis; Celecoxib; Myeloperoxidase; Reduced glutathione; Rofecoxib; Total nitric oxide synthetase

Indexed keywords

ACETIC ACID; CELECOXIB; GLUTATHIONE; HISTAMINE; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; ROFECOXIB; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION;

ACETIC ACID; ANIMALS; COLITIS; CYCLOOXYGENASE INHIBITORS; LACTONES; MALE; PYRAZOLES; RATS; RATS, WISTAR; SULFONAMIDES; SULFONES;

EID: 12344281097     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.11.036     Document Type: Article

References (50)

1. R.S. Balfour Cytokines in intestinal inflammation: pathophysiological and clinical considerations Gastroenterology 106 1994 533 539
2. K.E. Barret Involvement of histamine in a rat model of inflammatory bowel disease Gastroenterology 98 1990 A653
3. 2 J. Biol. Chem. 260 1985 6899 6906
4. P.D. Bradley, D.A. Friebal, and R.D. Christensen Measurements of cutaneous inflammation: estimation of neutrophil content with an enzyme marker J. Invest. Dermatol. 78 1982 206 209
5. G.F. Bonner Exacerbation of inflammatory bowel disease with use of celecoxib Am. J. Gastroenterol. 94 2001 1306 1308
6. E. Carty, M. DeBrabander, R.M. Feakins, and D.S. Rampton Measurement of in-vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper Gut 46 2000 487 492
7. C. Cho Current roles of nitric oxide in gastrointestinal disorders J. Physiol. (Paris) 95 2001 253 256
8. S.M. Cohn, S. Scloemann, T. Tessner, K. Seibert, and W.F. Stenson Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1 J. Clin. Invest. 99 1997 367 1379
9. S. Cuzzocrea, E. Mazzon, I. Serraino, L. Dugol, T. Centorrino, A. Ciccolo, L. Sautebin, and A.P. Caputi Celecoxib, a selective cyclooxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulphonic acid in rats Eur. J. Pharmacol. 431 2001 91 102
10. J.A. Dominitz, and E.S. Boyko Association between analgesic use and inflammatory bowel disease flares. A retrospective cohort study Gastroenterology 1184 2000 A3024
11. R. Eliakim, F. Karmeli, E. Razin, and D. Rachmilewitz Role of platelet activating factor in ulcerative colitis Gastroenterology 95 5 1988 1168 1171
12. R. Eliakim, F. Karmeli, E. Okon, and D. Rachmilewitz Ketotifen effectively prevents mucosal damage in experimental colitis Gut 33 1992 1498 1503
13. C.O. Elson, R.B. Sartor, G.S. Tennysion, and R.H. Riddel Experimental models of inflammatory bowel disease Gastroenterologist 109 1995 1344 1367
14. R. Fabia, A. Ar'Rajab, R. Willen, R. Anderson, and S. Bangmark Effect of putative phospholipase inhibitors on acetic acid-induced colitis in rats Br. J. Surg. 80 1993 1199 1204
15. J.B. Felder, B.I. Korelitz, and R. Rajapakes Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study Am. J. Gastroenterol. 95 2000 1949 1954
16. D. Gerd, and K. Werner Cyclooxygenase inhibitor-current status and future prospects Eur. J. Med. Chem. 36 2001 109 126
17. J.L. Goldstein, F.E. Silverstein, N.M. Agrawal, R.C. Hubbard, J. Kaiser, C.J. Maurath, K.M. Verburg, and G.S. Geis Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel Cox-2 inhibitor Am. J. Gastroenterol. 95 2000 1681 1690
18. M.B. Grisham, C. Volkmer, P. Tso, and T. Yamada Metabolism of trinitrobenzene sulphonic acid by the rat colon produces reactive oxygen species Gastroenterology 101 1991 540 547
19. X. Guo, W.P. Wang, J.K. Ko, and C.H. Cho Involvement of neutrophils and free radicals in the potentiating effects of passive cigarette smoking on inflammatory bowel disease in rats Gastroenterology 117 1999 884 892
20. X. Guo, E.S. Liu, J.K. Ko, B.C. Wong, Y. Ye, S. Lam, and C. Cho Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats Eur. J. Pharmacol. 411 2001 193 203
21. E. Kankuri, K. Vaali, R. Korpela, I. Paakkari, H. Vapaatalo, and E. Moilanen Effects of a Cox-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut Inflammation 25 2001 301 310
22. F. Karmeli, R. Eliakim, E. Okon, and D. Rachmilewitz Ketotifen and nitroxides decrease capsaicin-augmented ethanol-induced gastric damage in rats Dig. Dis. Sci. 40 1995 1140 1146
23. F. Karmeli, P. Cohen, and D. Rachmilewitz Cyclooxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats Eur. J. Gastroenterol. Hepatol. 12 2000 223 231
24. L. Kruidenier, and H.W. Verspaget Oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous? Aliment. Pharmacol. Ther. 16 2002 1997 2015
25. W. Lorenz, H. Barth, and J. Kushe Histamine in the pig determination distribution, release and pharmacological actions Eur. J. Pharmacol. 14 1971 155 175
26. U. Mahadevan, E.V. Loftus, and W.J. Tremaine Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease Am. J. Gastroenterol. 97 2001 910 914
27. A.A. Mahgoub Thymoquinone protects against experimental colitis in rats Toxicol. Lett. 143 2003 133 143
28. A.A. Mahgoub, A.H. El-Medany, D.A. Sabaht, and A.T.M.M. Ali Potential protective effects of sucralfate against acetic-induced colitis in rats JDP 4 2003 79 87
29. A.R. Martin, I. Villegas, C. La-Casa, and C. Alarcon de la Lastra The cyclooxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats Eur. J. Pharmacol. 481 2003 1 10
30. J.L. Masferrer, D.C. Isakson, and K. Seibert Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract Gastroenterol. Clin. North Am. 25 1996 363 372
31. W.K. McNaughton, S.S. Lowe, and K. Cushing Role of nitric oxide in inflammation induced suppression of secretion in a mouse model of acute colitis Am. J. Physiol. 275 1998 G1353 G1360
32. A.D. Millar, D.S. Rampton, C.L. Chander, A.W.D. Claxson, S. Blades, A. Coumbe, J. Panetta, C.J. Morris, and D.R. Blake Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis Gut 39 1996 407 415
33. M.J. Miller, H. Sadowska-Krowicka, S. Chotinaruemol, J.L. Kakkis, and D.A. Clark Amelioration of chronic ileitis by inducible nitric oxide synthase inhibition J. Pharmacol. Exp. Ther. 264 1993 11 16
34. G.P. Morris, P.L. Beck, M.S. Herridge, W.T. Depew, M.R. Szewczuk, and J.L. Wallace Hapten-induced model of chronic ulceration in the rat colon Gastroenterologist 96 1989 795 803
35. R.D. Newberry, W.F. Stenson, and R.G. Lorenz Cyclooxygenase-2 dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen Nat. Med. 5 1999 900 906
36. M.K. O'Bannion, H.B. Sadowsky, V. Winn, and D.A. Young A serum and glucocorticoid-regulated 4 kilobase mRNA encodes a cyclooxygenase-related protein J. Biol. Chem. 266 1991 23261 23267
37. C.W.J. Owens, and R.V. Belcher A colorimetric micromethod for determination of glutathione Biochem. J. 94 1965 705 711
38. D. Rachmilewitz, J.S. Stamler, D. Bachwich, F. Karmeli, Z. Ackerman, and D.K. Podolsky Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease Gut 36 1995 718 723
39. D. Rachmilewitz, F. Karmeli, E. Okon, and M. Bursztyn Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity Gut 37 1995 247 255
40. A.C. Rosam, J.L. Wallace, and B.J.R. Whittle Potent ulcerogenic actions of platelet-activating factor on the stomach Nature 319 1986 54 56
41. C. Salvatore, M. Amannuela, S. Ivana, D. Laura, C. Tommaso, C. Antonio, S. Lidia, and C. Achille Celecoxib, a selective cyclooxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats Eur. J. Pharmacol. 431 2001 91 102
42. B. Sido, V. Hack, A. Hochlehner, H. Lipps, C. Herfarth, and W. Droge Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease Gut 42 1998 485 492
43. I.I. Singer, D.W. Kawka, S. Schloemann, T. Tessner, T. Riehl, and W.F. Stenson Cyclooxygenase-2 is induced in colonic epithelial cells in inflammatory bowel disease Gastroenterology 115 1998 297 306
44. T. Tessner, S. Cohn, S. Schloemann, and W.F. Stenson Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice Gastroenterology 115 1998 874 882
45. J.L. Wallace, and A.W. Tigley Review article: new insights into prostaglandins and mucosal defence Aliment. Pharmacol. Ther. 9 1995 227 235
46. J.L. Wallace, P. Braquet, and G.C. Ibboston Assessment of the role of platelet activating factor in an animal model of inflammatory bowel disease J. Lipid Mediat. 1 1989 13 23
47. J.L. Wallace, C.M. Keenan, D. Gale, and T.S. Shoupe Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis Gastroenterology 102 1992 18 27
48. W. Xie, D.L. Robertson, and D.L. Simmons Mitogen inducible prostaglandin G/H synthase: a new target for nonsteroidal anti-inflammatory drugs Drug Dev. Res. 25 1992 249 265
49. T. Yamada, E. Destch, R.D. Specian, M.A. Perry, R.B. Sartor, and M.B. Grisham Mechanism of acute and chronic intestinal inflammation induced by indomethacin Inflammation 17 1993 641 662
50. G. Yue, L. Pi-Shiang, Y. Kingsley, F.S. Frank, G.N. Robert, L. Xiao, K.L. Kersti, W. Congli, L. King-The, and Y.K.W. Patrick Colon epithelial cell death in 2,4,6, trinitrobenzene sulfonic acid induced colitis is associated with increased inducible nitric-oxide synthase expression and peroxynitrite production J. Pharmacol. Exp. Ther. 297 2001 915 925